


**AMENDMENTS TO THE CLAIMS**

Please cancel Claims 36-49 and insert therefor Claims 50-62 as follow. This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1- 49 (Canceled)

50. (New) A compound of the formula (I):



wherein:

R<sup>1</sup> is selected from the group consisting of:

quinoline-6-yl, quinoline-7-yl, isoquinoline-7-yl, isoquinoline-6-yl, 2-methylquinoline-6-yl, isoquinoline-3-yl, 2-methoxyquinoline-6-yl, 3-methoxyquinoline-6-yl, 2-dimethylamino-quinoline-6-yl, 2-chloro-3-ethyl-quinoline-6-yl, 2-morpholine-4-yl-quinoline-6-yl, 2-(4-methylpiperazine-1-yl)-quinoline-6-yl, 2-pyrrolidine-1-yl-quinoline-6-yl, 2-methanesulfonyl-quinoline-6-yl, 2-isopropyl-methylamino-quinoline-6-yl, 2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoquinoline-6-yl, quinoxaline-6-yl, 1-oxo-isoindoline-5-yl, 2-isopropyl-1-oxo-isoindoline-5-yl, 2-(2,2-difluoroethyl)-1-oxo-isoindoline-5-yl, 2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoindoline-5-yl, 2-methyl-1-oxo-isoindoline-5-yl, 2-cyclopropyl-1-oxo-isoindoline-5-yl, 2-ethyl-1-oxo-isoindoline-5-yl, and 2-(2-hydroxy-1-methylethyl)-1-oxo-isoindoline-5-yl.

R<sup>2</sup> represents a substituent selected from the group consisting of:

hydrogen atom, lower alkyl group, cyano group, lower alkyloxy group, lower alkyloxycarbonyl group, and trialkylsilyl group;

R<sup>3</sup> is a phenyl group, which is unsubstituted or substituted with 1 to 3 groups selected from the group consisting of:

halogen atom, lower alkyl group, cyano group, nitro group, lower alkyloxy group, hydroxy group, and amino group, wherein the lower alkyl group may be substituted by a halogen atom;  
or a pharmaceutically acceptable salt thereof.

51. (New) The compound of Claim 50 wherein R<sup>1</sup> is 2-(2-hydroxy-2-methyl-propyl)-quinoline-6-yl.

52. (New) The compound of Claim 50 wherein R<sup>1</sup> is 2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoquinoline-6-yl.

53. (New) The compound of Claim 50 wherein R<sup>2</sup> represents a substituent selected from the group consisting of: lower alkyl group, and cyano group.

54. (New) A compound which is selected from the group consisting of:  
5-methyl-1-phenyl-4-(quinoline-6-yl)-1H-[1,2,3]triazole,  
4-(2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoquinoline-6-yl)-1-(4-fluorophenyl)-5-methyl-1H-[1,2,3]triazole, and  
1-(4-fluorophenyl)-5-methyl-4-(2-(2-hydroxy-2-methyl-propyl)-quinoline-6-yl)-1H-[1,2,3]triazole,  
or a pharmaceutically acceptable salt thereof.

55. (New) The compound of Claim 54 which is selected from the group consisting of:  
4-(2-(2-hydroxy-2-methyl-propyl)-1-oxo-isoquinoline-6-yl)-1-(4-fluorophenyl)-5-methyl-1H-[1,2,3]triazole;  
or a pharmaceutically acceptable salt thereof.

56. (New) A compound which is selected from the group consisting of:  
1-(4-fluorophenyl)-5-methyl-4-(2-(2-hydroxy-2-methyl-propyl)-quinoline-6-yl)-1H-[1,2,3]triazole,  
or a pharmaceutically acceptable salt thereof.

57. (New) The compound of Claim 56 which is:  
1-(4-fluorophenyl)-5-methyl-4-(2-(2-hydroxy-2-methyl-propyl)-quinoline-6-yl)-1H-[1,2,3]triazole.

58. (New) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 50, or a pharmaceutically acceptable salt thereof.

59. (New) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 54, or a pharmaceutically acceptable salt thereof.

60. (New) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 55, or a pharmaceutically acceptable salt thereof.

61. (New) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 56, or a pharmaceutically acceptable salt thereof.

62. (New) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 57, or a pharmaceutically acceptable salt thereof.